Amplification and Expression of the c-erbB-2 Oncogene in Müllerian-Derived Genital-Tract Tumors

This study focused on 18 uterine corpus tumors and 7 ovarian endometrioid tumors, all of them malignant and Müllerian derived. Differential polymerase chain reaction (DPCR), dot blot hybridization, and immunohistochemical technique were employed to determine c-erbB-2 amplification and expression. Of...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 1998-11, Vol.71 (2), p.165-171
Main Authors: Manavi, Mahmood, Berger, Andreas, Kucera, Elisabeth, Schneeweiß, Angelika, Kucera, Herwig, Kubista, Ernst, Czerwenka, Klaus
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
c-erbB-2 oncogene
differential polymerase chain reaction (DPCR)
Female
Female genital diseases
Genes, erbB-2
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry
Medical sciences
Middle Aged
Müllerian-derived tumor
Nucleic Acid Hybridization
Ovarian Neoplasms - genetics
Ovarian Neoplasms - mortality
Ovarian Neoplasms - pathology
ovary
Polymerase Chain Reaction
Prognosis
Receptor, ErbB-2 - analysis
Retrospective Studies
Tumors
uterine corpus
Uterine Neoplasms - genetics
Uterine Neoplasms - mortality
Uterine Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study focused on 18 uterine corpus tumors and 7 ovarian endometrioid tumors, all of them malignant and Müllerian derived. Differential polymerase chain reaction (DPCR), dot blot hybridization, and immunohistochemical technique were employed to determine c-erbB-2 amplification and expression. Of 25 Müllerian-derived tumors, 17 (68.0%) demonstrated amplified c-erbB-2 (two to eight copies) by DPCR. These 25 samples were reexamined by dot blot and immunohistochemical technique, revealing c-erbB-2 amplification and expression of to be 52.0 and 40.0%, respectively. There seemed to be a slight correlation between the amplification and expression of c-erbB-2 and patient survival. Although c-erbB-2 was frequently present in Müllerian-derived genital-tract tumors, it is uncertain whether this oncogene may serve as their sole prognostic marker. The question remains whether c-erbB-2 alone, or in conjunction with other oncogenes or suppressor genes, accounts for the pathogenesis of Müllerian-derived tumors. However, these results suggest for the first time in the literature that DPCR is a sensitive enough technique for detecting c-erbB-2 amplification in Müllerian-derived tumors.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.1998.5084